1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Teh Seng Pharmaceutical Mfg Co Ltd

Teh Seng Pharmaceutical Mfg Co Ltd

TTPEX:7860
76.70
TWD
0.00
(0.00%)
2.02BMarket Cap
Teh Seng Pharmaceutical Mfg Co Ltd
TPEX:7860
(Taipei Exchange)

Recent

price

76.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
TTM
TWD
25.51
28.21
26.41
- -
Revenue per Share
3.45
5.49
3.22
- -
Basic EPS, GAAP
6.17
5.73
2.86
- -
Free Cash Flow per Basic Share
1
2
2
- -
Dividend per Share
29.96
33.55
34.84
32.46
Book Value per Share
29.96
33.55
34.83
32.46
Tangible Book Value per Share
32
32
32
32
Basic Weighted Avg Shares
817
903
845
- -
Sales/Revenue/Turnover
15.24
20.96
16.65
- -
Operating Margin (%)
43
39
39
- -
Depreciation Expense
110
176
103
- -
Net Income, GAAP
23.22
20.64
23.46
- -
Effective Tax Rate (%)
13.53
19.46
12.19
- -
Profit Margin (%)
248
392
416
340
Working Capital
- -
- -
- -
- -
LT Debt
959
1,074
1,115
1,039
Total Equity
- -
12.07
8.48
- -
Return on Invested Capital (%)
- -
14.58
8.36
- -
Return on Capital (%)
- -
17.29
9.42
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
182
135
161
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
- -
2,426
2,016

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
746
698
650
Cash, Cash Equivalents & STI
436
407
332
Accounts Receivable, Net
103
101
109
Inventories
175
159
167
Total Current Liabilities
413
282
310
Payables & Accruals
- -
- -
- -
ST Debt
182
135
161
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
3.83%
Free Cash Flow
- -
- -
-50.06%
Net Income, GAAP
- -
- -
-41.34%
Sales/Revenue/Turnover
- -
- -
-6.36%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
903
2025
- -
- -
845
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5.49
2025
- -
- -
3.22
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2
2025
- -
- -
2
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Teh Seng Pharmaceutical Mfg. Co., Ltd. is a Taiwan-based pharmaceutical manufacturing company specializing in transdermal drug delivery systems (TDDS), topical therapeutic formulations, and herbal healthcare products. Founded in 1975 and headquartered in Tainan City, Taiwan, the company operates across prescription pharmaceuticals, over-the-counter (OTC) consumer health, traditional Chinese medicine, and contract development and manufacturing organization (CDMO/OEM/ODM) business segments. The company's core product portfolio comprises hydrogel cataplasms and transdermal pain relief patches; anti-inflammatory and analgesic medicated plasters formulated with active ingredients such as diclofenac, indomethacin, capsicum extract, and methyl salicylate; traditional herbal plaster preparations and botanical extracts; topical ointments, creams, sprays, and gels for dermatological and musculoskeletal applications; medical wound dressings and fever cooling sheets; and dietary health supplements. Teh Seng distributes its products to medical centers, clinics, retail pharmacy chains, and multinational pharmaceutical enterprises across Taiwan, North America, Japan, Europe, Southeast Asia, and Greater China. In recent developments, Teh Seng registered on the Taipei Exchange Emerging Stock Board under ticker 7860 to broaden its institutional investor base and finance strategic growth initiatives. The company has expanded its PIC/S GMP-certified manufacturing infrastructure with automated high-speed coating and packaging lines to increase production capacity for advanced TDDS patches. In addition, Teh Seng has deepened its strategic CDMO alliances with international pharmaceutical partners to co-develop next-generation controlled-release hydrogel formulations for pain management and topical therapies.